Lexaria Bioscience (LEXX) Non-Current Assets (2011 - 2026)
Lexaria Bioscience (LEXX) posted Non-Current Assets of $716462.0 for Q2 2026, little changed sequentially from $717021.0 in Q1 2026, and down 23.34% YoY from $934588.0 in Q2 2025.
Lexaria Bioscience (LEXX) Non-Current Assets (2011 - 2026) Analysis & Trends
Lexaria Bioscience has reported Non-Current Assets for 16 years, with the latest figure at $716462.0 in Q2 2026.
- Quarterly Non-Current Assets fell 23.34% year-over-year to $716462.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $716462.0 (down 23.34% YoY) and the FY2025 annual result came in at $706776.0, down 27.12% from the prior year.
- Non-Current Assets was little changed at $716462.0 in Q2 2026 per LEXX's latest filing, from $717021.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $1.0 million in Q2 2023 and troughed at $687678.0 in Q4 2025.
- A 5-year average of $868569.8 and a median of $890734.5 in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets slumped 31.29% in 2022, then climbed 18.63% in 2023.
- Over 5 years, Non-Current Assets stood at $854110.0 in 2022, then gained by 9.25% to $933140.0 in 2023, then increased by 3.74% to $968033.0 in 2024, then retreated by 28.96% to $687678.0 in 2025, then rose by 4.19% to $716462.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $716462.0, $717021.0, and $687678.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 18.06 Bn |
| 10 | Lexaria Bioscience | 10.14 Mn | 6.52 Mn | - | 716,462.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 716,462.00 |
| Feb 28, 2026 | 717,021.00 |
| Nov 30, 2025 | 687,678.00 |
| Aug 31, 2025 | 706,776.00 |
| May 31, 2025 | 934,588.00 |
| Feb 28, 2025 | 953,168.00 |
| Nov 30, 2024 | 968,033.00 |
| Aug 31, 2024 | 969,803.00 |
| May 31, 2024 | 925,058.00 |
| Feb 29, 2024 | 935,059.00 |
| Nov 30, 2023 | 933,140.00 |
| Aug 31, 2023 | 932,773.00 |
| May 31, 2023 | 1.00 Mn |
| Feb 28, 2023 | 851,198.00 |
| Nov 30, 2022 | 854,110.00 |
| Aug 31, 2022 | 856,411.00 |
| May 31, 2022 | 846,469.00 |
| Feb 28, 2022 | 842,362.00 |
| Nov 30, 2021 | 844,546.00 |
| Aug 31, 2021 | 823,877.00 |